Edwards Lifesciences Co. (NYSE:EW) Short Interest Update
Edwards Lifesciences Co. (NYSE:EW – Get Free Report) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 10,750,000 shares, a decline of 6.3% from the October 31st total of 11,470,000 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average trading volume of 4,100,000 shares, the days-to-cover ratio is currently 2.6 days.
Edwards Lifesciences Stock Performance
NYSE EW traded up $0.82 on Monday, hitting $69.18. 4,409,695 shares of the stock traded hands, compared to its average volume of 3,466,915. The firm has a market capitalization of $41.96 billion, a price-to-earnings ratio of 29.56, a PEG ratio of 3.82 and a beta of 1.01. The business’s fifty day moving average is $68.03 and its two-hundred day moving average is $77.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.45 and a current ratio of 3.28. Edwards Lifesciences has a 12 month low of $60.57 and a 12 month high of $94.87.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, hitting the consensus estimate of $0.59. The company had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.48 billion. Edwards Lifesciences had a return on equity of 24.54% and a net margin of 24.59%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 EPS. As a group, equities analysts anticipate that Edwards Lifesciences will post 2.51 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on EW. Citigroup reduced their price target on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. SVB Leerink assumed coverage on shares of Edwards Lifesciences in a research report on Monday, October 16th. They issued a “market perform” rating and a $75.00 price target on the stock. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, November 27th. Mizuho lowered their price objective on Edwards Lifesciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, October 26th. Finally, Stifel Nicolaus cut their target price on Edwards Lifesciences from $87.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $81.56.
Check Out Our Latest Report on Edwards Lifesciences
Insider Buying and Selling
In related news, VP Daveen Chopra sold 8,500 shares of Edwards Lifesciences stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $76.07, for a total transaction of $646,595.00. Following the completion of the transaction, the vice president now owns 23,950 shares of the company’s stock, valued at $1,821,876.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 8,500 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $76.07, for a total value of $646,595.00. Following the completion of the sale, the vice president now directly owns 23,950 shares in the company, valued at $1,821,876.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $65.30, for a total value of $391,800.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $2,579,545.90. The disclosure for this sale can be found here. Insiders have sold a total of 171,040 shares of company stock valued at $12,045,513 over the last ninety days. 1.29% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Edwards Lifesciences by 98,836.3% during the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 759,315,387 shares of the medical research company’s stock valued at $71,626,220,000 after buying an additional 758,547,908 shares during the period. Moneta Group Investment Advisors LLC lifted its stake in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares in the last quarter. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter valued at $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its position in shares of Edwards Lifesciences by 440.0% during the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock valued at $243,173,000 after purchasing an additional 2,860,000 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Edwards Lifesciences by 655.9% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after purchasing an additional 2,017,801 shares during the period. 79.25% of the stock is owned by institutional investors.
About Edwards Lifesciences (Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Edwards Lifesciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Edwards Lifesciences wasn’t on the list.
While Edwards Lifesciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Original: MarketBeat News Feed: Edwards Lifesciences Co. (NYSE:EW) Short Interest Update